The prevention and treatment of osteoporosis

Arthritis and Rheumatism

Volumn 11, Issue 2, 1998, Pages 124-134

  Golden, Brian D ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DROLOXIFENE; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; IBANDRONIC ACID; INTEGRIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IPRIFLAVONE; PAMIDRONIC ACID; PARATHYROID HORMONE; PROGESTERONE; PROTON PUMP INHIBITOR; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM; TAMOXIFEN; TILUDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D; ZOLENDRONATE;

BONE ATROPHY; BONE DENSITY; BONE MASS; BONE REMODELING; BONE TURNOVER; BREAST CANCER; BREAST DISEASE; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG APPROVAL; DRUG STRUCTURE; DRUG TARGETING; ENDOMETRIUM CANCER; ESOPHAGITIS; ESTROGEN THERAPY; FEMALE; FRACTURE; GENETIC ASSOCIATION; HOT FLUSH; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KINESIOTHERAPY; MENOPAUSE; NAUSEA; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOPHYSIOLOGY; POSTMENOPAUSE; RASH; REVIEW; SLOW RELEASE FORMULATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS; TRANSDERMAL DRUG ADMINISTRATION; TRANSDERMAL PATCH; VAGINA BLEEDING;

EID: 84988222724     PISSN: 0004-3591     EISSN: 1529-0131     Source Type: Journal    
DOI: 10.1002/art.1790110208     Document Type: Review

References (112)

1. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-50.
2. Raisz LG. Perspective: the osteoporosis revolution. Ann Intern Med 1997;126:458-62.
3. Parfitt AM. Quantum concept of bone remodeling and turnover: implications for pathogenesis of osteoporosis. Calcif Tissue Int 1979;28:1-5.
4. Arlot ME, Sornay-Rendu E, Garnero P, Vey-Marty B, Delmas PD. Apparent pre-and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res 1997;12: 683-90.
5. Heaney RP, Recker RR. Saville PD. Menopausal changes in bone remodeling. J Lab Clin Med 1978;92: 964-70.
6. Dempster DW, Lindsay R. Pathogenesis of osteoporosis. Lancet 1993;341:797-801.
7. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389-96.
8. Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med 1986;314:1676-86.
9. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-73.
10. Slemenda CW, Hui SL, Longcope C, Wellman H, Johnston CC Jr. Predictors of bone mass in perimenopausal women. Ann Intern Med 1990;112:96-101.
11. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-5.
12. Wasnich RD, Ross PD, Heilbrun LK, Vogel JM. Prediction of postmenopausal fracture risk with use of bone mineral measurements. Am J Obstet Gynecol 1985; 153:745-51.
13. Hui SL, Slemenda CW, Johnston CC Jr. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989;111:355-61.
14. Hui SL, Slemenda CW, Johnston CC Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988;81:1804-9.
15. Johnston CC Jr, Slemenda CW, Melton LJ III. Clinical use of bone densitometry. N Engl J Med 1991;324: 1105-9.
16. Kanis JA. Melton LJ III, Christiansen C, Johnston CC Jr, Khaltaev N. Perspective: the diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
17. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective: how many women have osteoporosis? J Bone Miner Res 1992;7:1005-10.
18. Melton LJ III. Osteoporosis: magnitude of the problem: worldwide and future. In: Osteoporosis: research advances and clinical applications: Fourth International Symposium on Osteoporosis, Washington, DC, June 4-7, 1997. Washington (DC): National Osteoporosis Foundation; 1997. p. 23.
19. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2:285-9.
20. Lindsay R. Estrogen therapy in the prevention and management of osteoporosis. Am J Obstet Gynecol 1987;156:1347-51.
21. Slemenda CW. Can we improve peak bone mass? In: Osteoporosis: research advances and clinical applications: Fourth International Symposium on Osteoporosis. Washington, DC, June 4-7, 1997. Washington (DC): National Osteoporosis Foundation; 1997. p. 32.
22. Ralston SH. Controls on genetics of bone: theory and fact. In: Osteoporosis: research advances and clinical applications: Fourth International Symposium on Osteoporosis, Washington, DC, June 4-7, 1997. Washington (DC): National Osteoporosis Foundation; 1997. p. 24.
23. Sainz J, van Tornot JM, Loro ML, Sayre J, Roe TF, Gilsanz V. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. N Engl J Med 1997;337:77-82.
24. Johnston CC Jr, Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992;327:82-7.
25. NIH Consensus Development Panel on Optimum Calcium Intake. Optimum calcium intake. JAMA 1994-272:1942-8.
26. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1992;327:620-7.
27. Wyshak G, Frisch RE, Albright TE, Albright NL, Schiff I, Witschi J. Nonalcoholic carbonated beverage consumption and bone fractures among women former college students. J Orthop Res 1989;7:91-9.
28. Aloia JF, Vaswani A, Yeh JK, Ross PL, Flaster E, Dilmanian FA. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 1994;120:97-103.
29. Simkin A, Ayalon J, Leichter I. Increased trabecular bone density due to bone-loading exercises in postmenopausal osteoporotic women. Calcif Tissue Int 1987;40:59-63.
30. Dalsky GP, Stocke KS, Ehsani AA, Slatopolosky E, Lee WC, Birge SJ. Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med 1988;108:824-8.
31. Nelson ME, Fiatarone MA, Morganti CM, Trice I, Greenberg RA, Evans WJ. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. JAMA 1994;272:1909-14.
32. Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis. JAMA 1941;116:2465-74.
33. Lindsay R, Aitken JM, Anderson JB, Hart DM, Mac-Donald EB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by estrogen. Lancet 1976;1: 1038-41.
34. Lindsay R. Prevention of spinal osteoporosis in oophorectomized women. Lancet 1980;2:1151-4.
35. Recker RR, Saville PD, Heaney RP. Effects of oestrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 1977;87:649-55.
36. Lindsay R, Hart DM, MacLean A, Clark AC, Kraszowski A, Garwood J. Bone response to termination of oestrogen treatment. Lancet 1978;1:1323-7.
37. Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459-61.
38. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
39. Weiss NA, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-8.
40. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9-16.
41. Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995;5:23-9.
42. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319-24.
43. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-71.
44. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
45. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991-325:756-62.
46. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-32.
47. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
48. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study): a randomized controlled trial. JAMA 1996;276:1397-403.
49. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.
50. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151:67-72.
51. Watts NB. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 1994;20:717-34.
52. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med 1997;336:558-66.
53. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17:137-44.
54. Reginster JY, Deroisy R, Denis D, Collette J, Lecart MP, Sarlet N, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989;79:1469-71.
55. Hosking DJ, McClung MR, Ravin P, Wasnich RD, Thompson DE, Daley MS, et al, for the EPIC Study Group. Alendronate in the prevention of osteoporosis: EPIC study two-year results. J Bone Miner Res 1996; 11 Suppl 1:S133.
56. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al, for the Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
57. Mortensen L, Bekker P, Ouweland F, Horowitz Z, Rupich R, DiGennaro J, et al. Prevention of early postmenopausal bone loss by risedronate [abstract]. J Bone Miner Res 1995;10:S140.
58. Steiniche T, Hasling C, Charles P, Eriksen EF, Moskilde L, Melsen F. A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 1989;10:313-20.
59. Heaney RP. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 1994;9:1515-23.
60. Christiansen C, Riis BJ. 17β-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990;71:836-41.
61. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990;76:290-5.
62. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
63. Lufkin EG, Riggs BL. Three-year follow-up on effects of transdermal estrogen [letter]. Ann Intern Med 1996; 125:77.
64. Quigley ME, Martin CL, Burmier AM, Brooks P. Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 1987;156:1516-23.
65. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322: 1265-71.
66. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
67. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95:557-67.
68. Marcus R. Cyclic etidronate: has the rose lost its bloom? Am J Med 1993;95:555-6.
69. Black DM, Cummings SR, Karpf DB, Cauler JA, Thompson DE, Nevitt MC, et al, for the Fracture Intervention Trial Research Group. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
70. DeGroen PC, Lubbe DF, Hirsch LJ, Dafotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
71. Reginster JY, Jeugmans-Huynen AM, Albert A, Denis D, Deroisy R, Lecart MP, et al. Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone. Bone 1988;9:349-54.
72. Reginster JYL. Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone 1992;13:351-4.
73. Chestnut CH III. Tiludronate: development as an osteoporosis therapy. Bone 1995;17 Suppl:517S-9S.
74. Skelid (tiludronate disodium) prescribing information. New York: Sanofi Pharmaceuticals, Inc.
75. Giannini S, D'Angelo A, Malvasi L, Castrignano R, Pati T, Tronca R, et al. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 1993;14:137-41.
76. Thiebaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994;4:76-83.
77. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer. J Clin Oncol 1997;15:955-62.
78. Wallach S. Calcitonin: history and prospects - a personal view. Semin Arthritis Rheum 1994;23:25-60.
79. Wallach S. Management of osteoporosis. Hosp Pract 1978;13:91-8.
80. Siminoski K, Josse RG. Calcitonin in the treatment of osteoporosis. Can Med Assoc J 1996;155:962-5.
81. Miacalcin package insert. East Hanover (NJ): Sandoz Pharmaceuticals Corporation.
82. Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides A, Tsekoura M. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 1991;49:369-72.
83. Overgaard K. Nasal salmon calcitonin in osteoporosis. Calcif Tissue Int 1994;55:79-81.
84. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556-61.
85. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994;55:82-6.
86. Reginster JY, Meurmans L, Deroisy R, Jupsin I, Biquet I, Albert A, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994;24:565-9.
87. Rochefort H. Mechanism of action of high-affinity antiestrogens. Am J Clin Oncol 1991;14 Suppl 2:S1-4.
88. Webster NJG, Green S, Jin JR, Chambon P. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 1988;54:199-207.
89. Grainger DJ, Metcalfe JC. Tamoxifen: teaching an old drug new tricks? Nat Med 1996;2:381-5.
90. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
91. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
92. Grey AB, Stapleton JP, Evans MC, Tatnell MA Ames RW, Reid IR. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995;99:636-41.
93. Kenny AM, Prestwood KM, Pilbeam CC, Raisz LG. The short-term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 1995;80:3287-91.
94. Neven P, DeMuylder X, van Belle Y. Tamoxifen-induced endometrial polyp [letter]. N Engl J Med 1997; 336:1389-90.
95. Ismail SM. Effects of tamoxifen on uterus [letter]. Lancet 1994;344:622-3.
96. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63-9.
97. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 1995;136:2435-41.
98. Chen HK, Ke HZ, Jee WSS, Ma YF, Pirie CM, Simmons HA, et al. Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy x-ray absorptiometric and histomorphometric study. J Bone Miner Res 1995;10:1256-62.
99. Eppenberger U, Wosikowski K, Kung W. Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol 1991;14 Suppl 2:S5-14.
100. Johnston CC Jr. Clinical applications of selective estrogen receptor modulators (SERMs) in the management of postmenopausal women (satellite symposium). In: Osteoporosis: research advances and clinical applications: Fourth International Symposium on Osteoporosis, Washington, DC, June 4-7, 1997. Washington (DC): National Osteoporosis Foundation; 1997. p. 20.
101. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993;14:690-709.
102. Reeve J, Arlot ME, Bradbeer JN, Hesp R, McAlly E, Meunier PJ, et al. Human parathyroid peptide treatment of vertebral osteoporosis. Osteoporos Int 1993; Suppl 1:5199-203.
103. Lane NE, Thompson JM, Strewler GJ, Kinney JH. Intermittent treatment with human parathyroid hormone (hPTH [1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. J Bone Miner Res 1995;10:1470-7.
104. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijoet OLM, Courpron P, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. BMJ 1980; 280:1340-4.
105. Lindsay R, Nieves J, Henneman E, Shen V, Cosman F. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone (1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993;77: 1535-9.
106. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994;331:1618-23.
107. Kleerekoper M, Mendlovic DB. Sodium fluoride therapy of postmenopausal osteoporosis. Endocr Rev 1993; 14:312-23.
108. Riggs BL, Hodgson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.
109. Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int 1991;1:155-61.
110. Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1995;123:401-8.
111. Mundy GR. Osteoporosis into the year 2010. Br J Obstet Gynecol 1996;103 Suppl 13:32-8.
112. Kimmel DB, Slovik DM, Lane NE. Current and investigational approaches for reversing established osteoporosis. Rheum Dis Clin North Am 1994;20:735-58.